GlassScriptPhysician profile
Michelle R Simmons
NPI 1306215660
$7,407.41
in general payments reported to CMS, 2019-2025
43 companies · $874 in 2025
The $874 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,287 · 2022: $1,615 · 2023: $1,816 · 2024: $1,815 · 2025: $874.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,505.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,504.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $1,310.30 | 2021-2024 | Belbuca, Xtampza |
| Abbvie INC. | $908.17 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $760.25 | 2021-2024 | Relistor |
| Forte Bio-Pharma LLC | $642.22 | 2021-2024 | Prolate, Nalocet |
| Scilex Pharmaceuticals INC. | $328.34 | 2021-2024 | Ztlido |
| Genzyme Corporation | $321.82 | 2023-2025 | |
| Biodelivery Sciences International, INC. | $213.72 | 2021 | |
| Averitas Pharma INC. | $195.50 | 2023-2025 | Qutenza |
| Merck Sharp & Dohme LLC | $190.27 | 2022-2023 | Belsomra, Verquvo |
| Lilly USA, LLC | $184.28 | 2021-2024 | Emgality, Reyvow |
| Abbott Laboratories | $180.08 | 2022-2024 | Freestyle Libre 3 |
| Medtronic, INC. | $152.17 | 2021-2025 | Intellis Adaptivestim, Inceptiv |
| Teva Pharmaceuticals USA, INC. | $134.99 | 2025 | Austedo Xr |
| Vertex Pharmaceuticals Incorporated | $127.81 | 2024-2025 | |
| Sk Life Science, INC. | $124.10 | 2024 | Xcopri |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $115.75 | 2025 | Prolastin-C Liquid |
| Bayer Healthcare Pharmaceuticals INC. | $115.42 | 2025 | |
| Spr Therapeutics, INC | $112.90 | 2023-2025 | Sprint Pns System |
| Amgen INC. | $104.18 | 2024 | Krystexxa |
| Pfizer INC. | $103.80 | 2021-2024 | |
| Kyowa Kirin, INC. | $95.72 | 2024 | Crysvita |
| Redhill Biopharma INC. | $80.11 | 2021 | |
| Valinor Pharma, LLC | $74.48 | 2023-2024 | Movantik |
| Ibsa Pharma INC. | $72.59 | 2021-2024 | Tirosint, Licart, Tirosint |
| Vertos Medical, INC. | $71.14 | 2022 | |
| Grt US Holding, INC. | $70.41 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $66.62 | 2022 | |
| Hikma Pharmaceuticals USA | $55.35 | 2022-2024 | Kloxxado |
| Brainsway USA INC | $53.57 | 2022 | |
| Almatica Pharma LLC | $48.92 | 2021 | |
| Uswm, LLC | $44.29 | 2021 | |
| Pacira Therapeutics, INC. | $42.03 | 2021 | |
| Lundbeck LLC | $40.73 | 2022-2023 | Vyepti |
| Arbor Pharmaceuticals, INC. | $38.08 | 2021-2022 | |
| Allergan, INC. | $34.61 | 2021-2022 | |
| Nevro Corp. | $33.45 | 2021-2022 | |
| Baudax Bio INC. | $29.18 | 2021 | |
| Boston Scientific Corporation | $28.51 | 2025 | Intracept |
| Saluda Medical Americas, INC. | $27.54 | 2024 | Evoke |
| Bioventus LLC | $19.01 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $18.96 | 2021 | |
| Avanos Medical | $18.20 | 2024 | Standard Rf Disposables |
| Kowa Pharmaceuticals America, INC. | $17.84 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Simmons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.